# Pomerantz LLP

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/pomerantz-llp
Canonical HTML page: https://gethealthbrief.com/entity/pomerantz-llp

## Timeline

- **2026-03-22**: Litigation Notice — Pomerantz LLP issues first public alert regarding the class action filing against Boston Scientific.
- **2026-02-23**: Form 8-K Filing — BSX files notice with the SEC regarding 'Other Events' involving executive shifts and operational updates.
- **2026-02-04**: Q4 2025 Earnings — Company reports financial results and provides updated guidance on clinical timelines.
- **2024-10-01**: AVANT GUARD Trial Pause — Boston Scientific announces a pause in its FARAPULSE PFA trial, citing the need for data review.

## Recent coverage (2 stories)

### Celcuity Stock Tanks 17.6% on Late Q3 Cancer Drug Launch; Pomerantz Investigates
2026-07-20 12:39:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Pomerantz LLP probes Celcuity after FDA-approved breast cancer therapy Revtorpyk sees delayed Q3 2026 commercial launch, sending shares down 17.6%. Analysts question prior launch readiness; health investors weigh biotech regulatory and execution risks.
Full story: https://gethealthbrief.com/story/celcuity-revtorpyk-launch-delay-pomerantz-investigation

### Boston Scientific Faces Class Action Scrutiny Over Alleged Disclosure Failures
2026-03-23 23:32:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pomerantz LLP has initiated a class action investigation and filing against Boston Scientific Corporation (BSX), alleging the medical device giant made misleading statements regarding its clinical trials and business prospects. The litigation follows a period of heightened volatility for the company's cardiovascular portfolio, specifically concerning the FARAPULSE PFA system and recent trial adjustments.
Full story: https://gethealthbrief.com/story/boston-scientific-pomerantz-class-action-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.